Improving Obesity and Metabolic Disorder Strains - Lactobacillus acidophilus JYLA-126 Achieves Latest Research Breakthrough

Obesity is a chronic metabolic disease caused by multiple factors, characterized by an increase in the volume and number of adipocytes in the body, 

resulting in an abnormally high percentage of body fat to body weight and excessive deposition of fat in certain areas. At present, the number of obese

 people in China has exceeded 250 million, and the trend is still on the rise. Overweight or obesity can increase the risk of breast cancer, coronary heart

 disease, type 2 diabetes, gallbladder disease, osteoarthritis, colon cancer, hypertension and stroke.

The R&D team of Zhongke Jiayi isolated and domesticated a strain of Lactobacillus acidophilus that improved obesity and metabolic disorders from 

fermented yogurt in Ili Prefecture, Xinjiang, and named it JYLA-126. It was deposited on July 8, 2019 at the General Microbiology Center of the China

 Microbial Species Collection and Management Committee.

This study combines microbiology, molecular biology, bioinformatics, and immunology to demonstrate the significant advantages of Lactobacillus 

acidophilus JYLA-126 in the prevention and treatment of obesity. It aims to create a safe, targeted, non-toxic, and cost-effective weight loss product 

for obese patients.

On December 5, 2023, the latest research achievement was obtained: Chen Tingtao from the School of Translational Medicine at Nanchang University 

published a research paper titled "Lactobacillus acidophilus JYLA-126 Ameliorates Obesity Associated Metabolic Disorders by Positively Regulating the

 AMPK Signaling Path Through the Gut Liver Axis" in Probiotics and Antimicrobial Proteins.

This study suggests that Lactobacillus acidophilus JYLA-126 can improve obesity symptoms in mice by activating the AMPK signaling pathway through

 the gut liver axis.